EMEA-002479-PIP01-18-M02 - paediatric investigation plan

Narsoplimab

Key facts

• Active substance:
  Narsoplimab
• Therapeutic area:
  Blood and lymphatic system disorders
• Decision number:
  P/0297/2024
• PIP number:
  EMEA-002479-PIP01-18-M02
• Pharmaceutical form(s):
  Solution for injection/infusion
• Condition(s) / indication(s):
  Treatment in haematopoietic stem cell transplantation
• Route(s) of administration:
  Intravenous use
• Decision type:
  PM: decision on the application for modification of an agreed PIP
• Decision date:
  16/08/2024
• Compliance check done:
  No

Decision

P/0297/2024: EMA decision of 16 August 2024 on the acceptance of a modification of an agreed paediatric investigation plan for narsoplimab, (EMEA- 002479-PIP01-18-M02)

Adopted Reference Number: EMA/364312/2024